Fennec Pharmaceuticals Inc.
FENC
$11.29
-$0.06-0.53%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 162.60% | 117.25% | -141.16% | 88.89% | 43.24% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 90.05% | 4.00% | -3.85% |
| Total Amortization of Deferred Charges | -- | -- | -71.58% | -42.86% | -43.48% |
| Total Other Non-Cash Items | -43.63% | 6.72% | 600.62% | -91.24% | 98.35% |
| Change in Net Operating Assets | -7.01% | 129.85% | -17,596.15% | 155.92% | 23.81% |
| Cash from Operations | 101.36% | 155.09% | -304.48% | 167.68% | 56.05% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -49.82% | -- | -- |
| Issuance of Common Stock | -- | 256.60% | 5,201.63% | -- | -- |
| Repurchase of Common Stock | -231.34% | -2,491.67% | -188.89% | 90.53% | -215.56% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 459.15% | 181.89% | 270.35% | 431.25% | -210.51% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 126.95% | 185.65% | 208.44% | 218.58% | 51.17% |